Reaction

Intracranial Aneurysm reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,959 reports · 84 co-occurring drugs

As of the last recalculation, Intracranial Aneurysm appears in 3,959 FAERS reports alongside 84 co-occurring drug terms. The strongest observed disproportionality signal is DIMENHYDRINATE (PRR 10.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Dimenhydrinate	21	10.4	10.4
Dolutegravir Sodium	12	7.0	7.0
Interferon Beta-1A	235	6.7	6.7
Diltiazem Hydrochloride Extended-Release Tablets	14	6.5	6.5
Romosozumab-Aqqg	16	6.2	6.2
Tolvaptan	17	6.2	6.2
Doxepin	11	5.7	5.7
Prasugrel Hydrochloride	11	5.7	5.7
Ticagrelor	34	5.6	5.6
Tizanidine	25	5.5	5.5
Valsartan And Hydrochlorothiazide	14	5.4	5.4
Tamsulosin Hydrochloride	20	5.2	5.2
Meclizine Hcl 12.5Mg	13	5.0	5.0
Meclizine Hcl 25Mg	13	5.0	5.0
Meclizine Hcl 12.5 Mg	13	5.0	5.0
Meclizine Hcl 25 Mg	13	5.0	5.0
Doxepin Hydrochloride	12	5.0	5.0
Tizanidine Hydrochloride	17	5.0	5.0
Calcium, Magnesium, Potassium, And Sodium Oxybates	8	4.9	4.9
Peginterferon Beta-1A	11	4.4	4.4
Extended Phenytoin Sodium	14	4.4	4.4
Meclizine	13	4.2	4.2
Darunavir	12	4.2	4.2
Ranolazine	8	4.0	4.0
Agalsidase Beta	7	4.0	4.0
Diroximel Fumarate	9	4.0	4.0
Gemfibrozil	11	3.8	3.8
Clopidogrel	140	3.8	3.8
Meclizine Hydrochloride	14	3.8	3.8
Tiotropium Bromide Inhalation Spray	8	3.8	3.8
Interferon Beta-1B	13	3.6	3.6
Esketamine Hydrochloride	11	3.2	3.3
Siponimod	5	2.9	3.0
Sofosbuvir	11	2.9	2.9
Amlodipine Besylate And Valsartan	6	2.9	2.9
Etonogestrel And Ethinyl Estradiol	12	2.9	2.9
Nintedanib	16	2.7	2.7
Nilotinib	15	2.7	2.7
Drospirenone And Ethinyl Estradiol	22	2.6	2.6
Paricalcitol	7	2.6	2.6
Adalimumab	332	2.6	2.6
Dimethyl Fumarate	60	2.6	2.6
Amphetamine	4	2.5	2.5
Fluticasone Propionate And Salmeterol	20	2.5	2.5
Upadacitinib	38	2.5	2.5
Risankizumab-Rzaa	37	2.4	2.4
Linaclotide	12	2.4	2.4
Eptinezumab-Jjmr	4	2.3	2.3
Acetaminophen, Aspirin, And Caffeine	9	2.2	2.2
Acetaminophen, Aspirin (Nsaid) And Caffeine	7	2.2	2.2
Niraparib	9	2.1	2.1
Benralizumab	8	2.1	2.1
Fam-Trastuzumab Deruxtecan-Nxki	4	2.1	2.1
Dabigatran Etexilate Mesylate	28	2.0	2.0
Varenicline Tartrate	30	2.0	2.0
Faricimab	3	1.9	1.9
Iohexol	3	1.9	1.9
Dabigatran Etexilate	28	1.9	1.9
Fremanezumab-Vfrm	4	1.8	1.8
Belimumab	11	1.8	1.8
Ustekinumab	35	1.8	1.8
Vismodegib	3	1.8	1.8
Fingolimod Hcl	29	1.8	1.8
Teriparatide	36	1.7	1.7
Axitinib	6	1.6	1.6
Hydrocodone Bitartrate And Acetaminophen	17	1.6	1.6
Conjugated Estrogens And Medroxyprogesterone Acetate	7	1.6	1.6
Natalizumab	50	1.5	1.5
Glecaprevir And Pibrentasvir	3	1.4	1.4
Methoxy Polyethylene Glycol-Epoetin Beta	3	1.4	1.4
Dalfampridine	19	1.4	1.4
Aflibercept	8	1.3	1.3
Ixekizumab	9	1.3	1.3
Alirocumab	6	1.3	1.3
Rimegepant Sulfate	3	1.2	1.2
Ambrisentan	29	1.2	1.2
Galcanezumab-Gnlm	7	1.2	1.2
Apremilast	30	1.1	1.1
Bimekizumab	4	1.0	1.0
Hydrocodone Bitartrate	8	1.0	1.0
Tapentadol Hydrochloride	6	0.9	0.9
Erenumab-Aooe	9	0.9	0.9
Cinacalcet Hydrochloride	6	0.7	0.7
Evolocumab	19	0.6	0.6

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.